| Nov 8 |
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)
|
| Nov 7 |
Keros Therapeutics reports Q3 results
|
| Nov 6 |
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
|
| Nov 6 |
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
|
| Nov 5 |
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
|
| Oct 16 |
Keros Therapeutics names Yung Chyung as chief medical officer
|
| Oct 16 |
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
|
| Sep 12 |
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
|
| Sep 5 |
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
|
| Sep 3 |
Keros gains after trial update on lung disorder therapy
|
